Rami Sherif1, Brahm H Segal. 1. Department of Medicine, Roswell Park Cancer Institute, School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, New York 14263, USA.
Abstract
PURPOSE OF REVIEW: When functioning properly, the immune system recognizes inhaled fungi and controls their growth, while avoiding injurious inflammation and allergy. 'Aspergillosis' represents a spectrum of clinical diseases resulting from impaired or excessive immune responses. Invasive aspergillosis is principally disease of severely immunocompromised patients, whereas allergic forms of aspergillosis result from an excessive inflammatory response to hyphae colonizing the sinopulmonary tract. We will review insights gained in host defense against Aspergillus species and the immunopathogenesis of Aspergillus-related diseases as well as important advances made in fungal diagnostics and antifungal therapy. RECENT FINDINGS: Important advances have been made in diagnosis of invasive aspergillosis and in antifungal agents. Voriconazole was superior to amphotericin B deoxycholate as primary therapy for invasive aspergillosis. There is significant interest in combination antifungal therapy for invasive aspergillosis. Fungal genomics offers a powerful opportunity to gain knowledge about fungal virulence factors that can be targets for drug development. In addition, new insights have been gained regarding host defense against Aspergillus species that may be exploited therapeutically. SUMMARY: We have gained substantial knowledge regarding how the immune system recognizes inhaled fungi and calibrates the inflammatory response. There has also been substantial progress in tools to diagnose aspergillosis and in antifungal therapeutics. Future progress will likely involve the development of more refined diagnostic tools, new classes of antifungal agents, and greater knowledge of pathogen and host factors that predispose to aspergillosis.
PURPOSE OF REVIEW: When functioning properly, the immune system recognizes inhaled fungi and controls their growth, while avoiding injurious inflammation and allergy. 'Aspergillosis' represents a spectrum of clinical diseases resulting from impaired or excessive immune responses. Invasive aspergillosis is principally disease of severely immunocompromised patients, whereas allergic forms of aspergillosis result from an excessive inflammatory response to hyphae colonizing the sinopulmonary tract. We will review insights gained in host defense against Aspergillus species and the immunopathogenesis of Aspergillus-related diseases as well as important advances made in fungal diagnostics and antifungal therapy. RECENT FINDINGS: Important advances have been made in diagnosis of invasive aspergillosis and in antifungal agents. Voriconazole was superior to amphotericin B deoxycholate as primary therapy for invasive aspergillosis. There is significant interest in combination antifungal therapy for invasive aspergillosis. Fungal genomics offers a powerful opportunity to gain knowledge about fungal virulence factors that can be targets for drug development. In addition, new insights have been gained regarding host defense against Aspergillus species that may be exploited therapeutically. SUMMARY: We have gained substantial knowledge regarding how the immune system recognizes inhaled fungi and calibrates the inflammatory response. There has also been substantial progress in tools to diagnose aspergillosis and in antifungal therapeutics. Future progress will likely involve the development of more refined diagnostic tools, new classes of antifungal agents, and greater knowledge of pathogen and host factors that predispose to aspergillosis.
Authors: Michael J Cornell; Intikhab Alam; Darren M Soanes; Han Min Wong; Cornelia Hedeler; Norman W Paton; Magnus Rattray; Simon J Hubbard; Nicholas J Talbot; Stephen G Oliver Journal: Genome Res Date: 2007-11-05 Impact factor: 9.043
Authors: Brahm H Segal; Alison G Freifeld; Lindsey Robert Baden; Arthur E Brown; Corey Casper; Erik Dubberke; Michael Gelfand; John N Greene; Michael G Ison; James I Ito; Judith E Karp; Daniel R Kaul; Earl King; Emily Mackler; Guido Marcucci; Jose G Montoya; Ashley Morris Engemann; Ken Rolston; Angelina S The Journal: J Natl Compr Canc Netw Date: 2008-02 Impact factor: 11.908
Authors: Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson Journal: Clin Infect Dis Date: 2008-02-01 Impact factor: 9.079
Authors: Wouter Meersseman; Katrien Lagrou; Johan Maertens; Alexander Wilmer; Greet Hermans; Steven Vanderschueren; Isabel Spriet; Eric Verbeken; Eric Van Wijngaerden Journal: Am J Respir Crit Care Med Date: 2007-09-20 Impact factor: 21.405
Authors: Luigina Romani; Francesca Fallarino; Antonella De Luca; Claudia Montagnoli; Carmen D'Angelo; Teresa Zelante; Carmine Vacca; Francesco Bistoni; Maria C Fioretti; Ursula Grohmann; Brahm H Segal; Paolo Puccetti Journal: Nature Date: 2008-01-10 Impact factor: 49.962
Authors: Natalie D Fedorova; Nora Khaldi; Vinita S Joardar; Rama Maiti; Paolo Amedeo; Michael J Anderson; Jonathan Crabtree; Joana C Silva; Jonathan H Badger; Ahmed Albarraq; Sam Angiuoli; Howard Bussey; Paul Bowyer; Peter J Cotty; Paul S Dyer; Amy Egan; Kevin Galens; Claire M Fraser-Liggett; Brian J Haas; Jason M Inman; Richard Kent; Sebastien Lemieux; Iran Malavazi; Joshua Orvis; Terry Roemer; Catherine M Ronning; Jaideep P Sundaram; Granger Sutton; Geoff Turner; J Craig Venter; Owen R White; Brett R Whitty; Phil Youngman; Kenneth H Wolfe; Gustavo H Goldman; Jennifer R Wortman; Bo Jiang; David W Denning; William C Nierman Journal: PLoS Genet Date: 2008-04-11 Impact factor: 5.917
Authors: A Oliva; P Flori; C Hennequin; J-C Dubus; M Reynaud-Gaubert; D Charpin; J M Vergnon; P Gay; A Colly; R Piarroux; H Pelloux; S Ranque Journal: J Clin Microbiol Date: 2014-11-12 Impact factor: 5.948